Top

Published in:

01-12-2017

Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals

Authors: Kelly L. Stauch, Katy Emanuel, Benjamin G. Lamberty, Brenda Morsey, Howard S. Fox

Published in: Journal of NeuroVirology | Issue 6/2017

Abstract

The use of antiretroviral (ARV) drugs with central nervous system (CNS) penetration effectiveness (CPE) may be useful in the treatment of HIV-associated neurocognitive disorder (HAND) as well as targeting a CNS reservoir in strategies to achieve a functional cure for HIV. However, increased cognitive deficits are linked to at least one of these drugs (efavirenz). As mitochondrial dysfunction has been found with a number of ARVs, and as such can affect neuronal function, the objective of this study was to assess the effects of ARV with high CPE for toxicological profiles on presynaptic nerve terminal energy metabolism. This subcellular region is especially vulnerable in that a constant supply of ATP is required for the proper maintenance of neurotransmitter release and uptake supporting proper neuronal function. We evaluated the effects of acute treatment with ten different high CPE ARVs from five different drug classes on rat cortical and striatal nerve terminal bioenergetic function. While cortical nerve terminal bioenergetics were not altered, striatal nerve terminals exposed to efavirenz, nevirapine, abacavir, emtricitabine, zidovudine, darunavir, lopinavir, raltegravir, or maraviroc (but not indinavir) exhibit reduced mitochondrial spare respiratory capacity (SRC). Further examination of efavirenz and maraviroc revealed a concentration-dependent impairment of striatal nerve terminal maximal mitochondrial respiration and SRC as well as a reduction of intraterminal ATP levels. Depletion of ATP at the synapse may underlie its dysfunction and contribute to neuronal dysfunction in treated HIV infection.

Available only for authorised users

Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, Rosebush PI (2012) The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J Clin Psychiatry 73:506–512CrossRefPubMed

Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV (2015) Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother 70:2693–2708CrossRefPubMed

Blas-Garcia A, Apostolova N, Ballesteros D, Monleon D, Morales JM, Rocha M, Victor VM, Esplugues JV (2010) Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52:115–125CrossRefPubMed

Blas-Garcia A, Polo M, Alegre F, Funes HA, Martinez E, Apostolova N, Esplugues JV (2014) Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. J Antimicrob Chemother 69:2995–3000CrossRefPubMed

Blas-Garcia A, Marti-Rodrigo A, Victor VM, Polo M, Alegre F, Funes HA, Apostolova N, Esplugues JV (2016) The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction. J Antimicrob Chemother 71:916–926CrossRefPubMed

Brand MD (1990) The contribution of the leak of protons across the mitochondrial inner membrane to standard metabolic rate. J Theor Biol 145:267–286CrossRefPubMed

Brandmann M, Nehls U, Dringen R (2013) 8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug efavirenz, stimulates the glycolytic flux in cultured rat astrocytes. Neurochem Res 38:2524–2534CrossRefPubMed

Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernan MA, Collaboration H-C (2014) Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 83:134–141CrossRefPubMedPubMedCentral

Caron M, Auclair M, Lagathu C, Lombes A, Walker UA, Kornprobst M, Capeau J (2004) The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 18:2127–2136CrossRefPubMed

Choi SW, Gerencser AA, Nicholls DG (2009) Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J Neurochem 109:1179–1191CrossRefPubMedPubMedCentral

Choi SW, Gerencser AA, Lee DW, Rajagopalan S, Nicholls DG, Andersen JK, Brand MD (2011) Intrinsic bioenergetic properties and stress sensitivity of dopaminergic synaptosomes. J Neurosci 31:4524–4534CrossRefPubMedPubMedCentral

Choi DY, Lee MK, Hong JT (2013) Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Neurobiol Dis 49:159–168CrossRefPubMed

Decloedt EH, Maartens G (2013) Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf 12:841–846CrossRefPubMed

Deng W, Baki L, Yin J, Zhou H, Baumgarten CM (2010) HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS. J Mol Cell Cardiol 49:746–752CrossRefPubMedPubMedCentral

Dunkley PR, Jarvie PE, Robinson PJ (2008) A rapid Percoll gradient procedure for preparation of synaptosomes. Nat Protoc 3:1718–1728CrossRefPubMed

Eggers C, Arendt G, Hahn K, Husstedt IW, Maschke M, Neuen-Jacob E, Obermann M, Rosenkranz T, Schielke E, Straube E, German Association of Neuro AuN-I (2017) HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol 264:1715–1727CrossRefPubMedPubMedCentral

El Hoss S, Bahr GM, Echtay KS (2015) Lopimune-induced mitochondrial toxicity is attenuated by increased uncoupling protein-2 level in treated mouse hepatocytes. Biochem J 468:401–407CrossRefPubMed

Fern R (2003) Variations in spare electron transport chain capacity: the answer to an old riddle? J Neurosci Res 71:759–762CrossRefPubMed

Flynn JM, Choi SW, Day NU, Gerencser AA, Hubbard A, Melov S (2011) Impaired spare respiratory capacity in cortical synaptosomes from Sod2 null mice. Free Radic Biol Med 50:866–873CrossRefPubMedPubMedCentral

Funes HA, Apostolova N, Alegre F, Blas-Garcia A, Alvarez A, Marti-Cabrera M, Esplugues JV (2014) Neuronal bioenergetics and acute mitochondrial dysfunction: a clue to understanding the central nervous system side effects of efavirenz. J Infect Dis 210:1385–1395CrossRefPubMed

Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N (2015) Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. J Antimicrob Chemother 70:2249–2254CrossRefPubMed

Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ (2016) Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS 30:591–600CrossRefPubMed

Gerencser AA, Neilson A, Choi SW, Edman U, Yadava N, Oh RJ, Ferrick DA, Nicholls DG, Brand MD (2009) Quantitative microplate-based respirometry with correction for oxygen diffusion. Anal Chem 81:6868–6878CrossRefPubMedPubMedCentral

Groener JB, Seybold U, Vollbrecht T, Bogner JR (2011) Short communication: decrease in mitochondrial transmembrane potential in peripheral blood mononuclear cells of HIV-uninfected subjects undergoing HIV postexposure prophylaxis. AIDS Res Hum Retrovir 27:969–972CrossRefPubMed

Harris M, Larsen G, Montaner JS (2008) Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 22:1890–1892CrossRefPubMed

Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, JC MA, Morgello S, Simpson DM, JA MC, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096CrossRefPubMedPubMedCentral

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C, Group H (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neuro-Oncol 17:3–16

Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR (2004) Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 4:117–131CrossRefPubMed

Imaizumi N, Kwang Lee K, Zhang C, Boelsterli UA (2015) Mechanisms of cell death pathway activation following drug-induced inhibition of mitochondrial complex I. Redox Biol 4:279–288CrossRefPubMedPubMedCentral

Jekabsons MB, Nicholls DG (2004) In situ respiration and bioenergetic status of mitochondria in primary cerebellar granule neuronal cultures exposed continuously to glutamate. J Biol Chem 279:32989–33000CrossRefPubMed

Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, Dugas TR (2007) HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol 224:60–71CrossRefPubMed

Jin J, Grimmig B, Izzo J, Brown LA, Hudson C, Smith AJ, Tan J, Bickford PC, Giunta B (2016) HIV non-nucleoside reverse transcriptase inhibitor efavirenz reduces neural stem cell proliferation in vitro and in vivo. Cell Transplant 25(11):1967–1977CrossRefPubMedPubMedCentral

Lagathu C, Eustace B, Prot M, Frantz D, Gu Y, Bastard JP, Maachi M, Azoulay S, Briggs M, Caron M, Capeau J (2007) Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 12:489–500PubMed

Lepeta K, Lourenco MV, Schweitzer BC, Martino Adami PV, Banerjee P, Catuara-Solarz S, de La Fuente RM, Guillem AM, Haidar M, Ijomone OM, Nadorp B, Qi L, Perera ND, Refsgaard LK, Reid KM, Sabbar M, Sahoo A, Schaefer N, Sheean RK, Suska A, Verma R, Vicidomini C, Wright D, Zhang XD, Seidenbecher C (2016) Synaptopathies: synaptic dysfunction in neurological disorders—a review from students to students. J Neurochem 138:785–805CrossRefPubMedPubMedCentral

Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137–142PubMedPubMedCentral

Letendre SL, JA MC, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ, Group H (2004) Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56:416–423CrossRefPubMed

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, JC MA, JA MC, Morgello S, Simpson D, Grant I, Ellis RJ, Group C (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70CrossRefPubMedPubMedCentral

Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, JC MA, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL, Group C (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neuro-Oncol 22:170–178

Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW, Miller RJ (1998) Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 95:14500–14505CrossRefPubMedPubMedCentral

Modica-Napolitano JS (1993) AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun 194:170–177CrossRefPubMed

Nagiah S, Phulukdaree A, Chuturgoon A (2015) Mitochondrial and oxidative stress response in HepG2 cells following acute and prolonged exposure to antiretroviral drugs. J Cell Biochem 116:1939–1946CrossRefPubMed

Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM (2014) Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neuro-Oncol 20:571–582

Palop JJ, Chin J, Mucke L (2006) A network dysfunction perspective on neurodegenerative diseases. Nature 443:768–773CrossRefPubMed

Pandya JD, Royland JE, MacPhail RC, Sullivan PG, Kodavanti PR (2016) Age- and brain region-specific differences in mitochondrial bioenergetics in Brown Norway rats. Neurobiol Aging 42:25–34CrossRefPubMed

Park MH, Lee YK, Lee YH, Kim YB, Yun YW, Nam SY, Hwang SJ, Han SB, Kim SU, Hong JT (2009) Chemokines released from astrocytes promote chemokine receptor 5-mediated neuronal cell differentiation. Exp Cell Res 315:2715–2726CrossRefPubMed

Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA (2011) Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. BioTechniques 50:98–115CrossRefPubMedPubMedCentral

Purnell PR, Fox HS (2014) Efavirenz induces neuronal autophagy and mitochondrial alterations. J Pharmacol Exp Ther 351:250–258CrossRefPubMedPubMedCentral

Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neuro-Oncol 18:388–399

Salabei JK, Gibb AA, Hill BG (2014) Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat Protoc 9:421–438CrossRefPubMedPubMedCentral

Sanchez AB, Varano GP, de Rozieres CM, Maung R, Catalan IC, Dowling CC, Sejbuk NE, Hoefer MM, Kaul M (2015) Antiretrovirals, methamphetamine, and HIV-1 envelope protein gp120 compromise neuronal energy homeostasis in association with various degrees of synaptic and neuritic damage. Antimicrob Agents Chemother 60:168–179CrossRefPubMedPubMedCentral

Sauerbeck A, Pandya J, Singh I, Bittman K, Readnower R, Bing G, Sullivan P (2011) Analysis of regional brain mitochondrial bioenergetics and susceptibility to mitochondrial inhibition utilizing a microplate based system. J Neurosci Methods 198:36–43CrossRefPubMedPubMedCentral

Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment. Nat Rev Neurol 12:309CrossRefPubMed

Shah A, Gangwani MR, Chaudhari NS, Glazyrin A, Bhat HK, Kumar A (2016) Neurotoxicity in the post-HAART era: caution for the antiretroviral therapeutics. Neurotox Res 30(4):677–697CrossRefPubMedPubMedCentral

Sorce S, Bonnefont J, Julien S, Marq-Lin N, Rodriguez I, Dubois-Dauphin M, Krause KH (2010) Increased brain damage after ischaemic stroke in mice lacking the chemokine receptor CCR5. Br J Pharmacol 160:311–321CrossRefPubMedPubMedCentral

Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S (2013) Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway. Free Radic Biol Med 65:778–788CrossRefPubMed

Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY (2011) Long-term safety from the raltegravir clinical development program. Curr HIV Res 9:40–53CrossRefPubMedPubMedCentral

Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ (2012) Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 343:696–703CrossRefPubMedPubMedCentral

Treisman GJ, Soudry O (2016) Neuropsychiatric effects of HIV antiviral medications. Drug Saf 39:945–957CrossRefPubMed

Valcour V, Paul R, Chiao S, Wendelken LA, Miller B (2011) Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis 53:836–842CrossRefPubMedPubMedCentral

Valenti D, Atlante A, Barile M, Passarella S (2002) Inhibition of phosphate transport in rat heart mitochondria by 3′-azido-3′-deoxythymidine due to stimulation of superoxide anion mitochondrial production. Biochem Pharmacol 64:201–206CrossRefPubMed

van Spronsen M, Hoogenraad CC (2010) Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep 10:207–214CrossRefPubMedPubMedCentral

Viengchareun S, Caron M, Auclair M, Kim MJ, Frachon P, Capeau J, Lombes M, Lombes A (2007) Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther 12:919–929PubMed

Wang X, Chai H, Lin PH, Yao Q, Chen C (2009a) Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 174:771–781CrossRefPubMedPubMedCentral

Wang X, Liao D, Lin PH, Yao Q, Chen C (2009b) Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells. Lab Investig 89:1355–1363CrossRefPubMedPubMedCentral

Whittaker VP (1993) Thirty years of synaptosome research. J Neurocytol 22:735–742CrossRefPubMed

Xu J, Chen Q, Zen K, Zhang C, Zhang Q (2013) Synaptosomes secrete and uptake functionally active microRNAs via exocytosis and endocytosis pathways. J Neurochem 124:15–25CrossRefPubMed

Yadava N, Nicholls DG (2007) Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J Neurosci 27:7310–7317CrossRefPubMed

Yang NC, Ho WM, Chen YH, Hu ML (2002) A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP. Anal Biochem 306:323–327CrossRefPubMed

Title: Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals
Authors: Kelly L. Stauch
Katy Emanuel
Benjamin G. Lamberty
Brenda Morsey
Howard S. Fox
Publication date: 01-12-2017
Publisher: Springer International Publishing
Published in: Journal of NeuroVirology / Issue 6/2017
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-017-0573-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

A neuropathic pain syndrome associated with hantavirus infection

Treatment of Theiler’s virus-induced demyelinating disease with teriflunomide

Progressive multifocal leukoencephalopathy 11 years after liver transplantation: a case report

Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis

Resting-state functional magnetic resonance imaging in clade C HIV: within-group association with neurocognitive function

Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review